Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
July 12, 2023 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
June 21, 2023 09:00 ET
|
Lumos Pharma, Inc.
Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE...
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
May 25, 2023 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone...
Lumos Pharma to Participate in World Orphan Drug Congress USA
May 22, 2023 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone...
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
May 08, 2023 08:00 ET
|
Lumos Pharma, Inc.
Oral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD OraGrowtH212 Interim Data Demonstrate LUM-201...
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
May 03, 2023 16:05 ET
|
Lumos Pharma, Inc.
-- Patient Enrollment Completed in both Phase 2 OraGrowtH Trials ---- Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 ---- Interim Data from OraGrowtH Trials Accepted for Presentation...
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
April 27, 2023 09:00 ET
|
Lumos Pharma, Inc.
Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas, April 27, 2023 (GLOBE...
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
March 09, 2023 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
March 05, 2023 14:00 ET
|
Lumos Pharma, Inc.
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in...